Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventral Tegmental Area | 12 | 2018 | 74 | 2.970 |
Why?
|
| Dopamine | 9 | 2017 | 474 | 1.910 |
Why?
|
| Prefrontal Cortex | 5 | 2022 | 640 | 1.720 |
Why?
|
| Drug-Seeking Behavior | 4 | 2019 | 213 | 1.470 |
Why?
|
| Toluene | 7 | 2007 | 37 | 1.400 |
Why?
|
| Cocaine | 4 | 2019 | 555 | 1.250 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 3 | 2018 | 24 | 1.170 |
Why?
|
| Cocaine-Related Disorders | 3 | 2018 | 504 | 0.890 |
Why?
|
| Neuralgia | 1 | 2022 | 27 | 0.830 |
Why?
|
| Neurons | 6 | 2008 | 881 | 0.750 |
Why?
|
| Chronic Pain | 1 | 2022 | 110 | 0.750 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2018 | 208 | 0.680 |
Why?
|
| Rats | 15 | 2022 | 5300 | 0.660 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2018 | 68 | 0.660 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 146 | 0.640 |
Why?
|
| KCNQ Potassium Channels | 1 | 2018 | 8 | 0.620 |
Why?
|
| Neural Inhibition | 3 | 2017 | 80 | 0.620 |
Why?
|
| Synapses | 3 | 2014 | 222 | 0.620 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2019 | 2083 | 0.590 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 290 | 0.590 |
Why?
|
| Cues | 2 | 2019 | 654 | 0.580 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2017 | 152 | 0.570 |
Why?
|
| Corticotropin-Releasing Hormone | 3 | 2018 | 79 | 0.570 |
Why?
|
| Pyramidal Cells | 2 | 2017 | 79 | 0.570 |
Why?
|
| Central Nervous System Depressants | 1 | 2018 | 182 | 0.560 |
Why?
|
| Mesencephalon | 2 | 2008 | 41 | 0.560 |
Why?
|
| Animals | 21 | 2022 | 20881 | 0.530 |
Why?
|
| Glutamic Acid | 4 | 2014 | 332 | 0.510 |
Why?
|
| Interneurons | 3 | 2010 | 70 | 0.510 |
Why?
|
| Cannabinoid Receptor Modulators | 2 | 2005 | 16 | 0.500 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 274 | 0.500 |
Why?
|
| Endocannabinoids | 2 | 2005 | 32 | 0.490 |
Why?
|
| Nucleus Accumbens | 3 | 2007 | 417 | 0.440 |
Why?
|
| Learning | 1 | 2015 | 186 | 0.430 |
Why?
|
| Action Potentials | 5 | 2018 | 223 | 0.410 |
Why?
|
| Piperidines | 3 | 2018 | 123 | 0.410 |
Why?
|
| Ethanol | 1 | 2018 | 893 | 0.400 |
Why?
|
| Pyrazoles | 3 | 2018 | 190 | 0.390 |
Why?
|
| Motor Activity | 3 | 2018 | 621 | 0.330 |
Why?
|
| Benzodiazepines | 1 | 2010 | 130 | 0.330 |
Why?
|
| Intracellular Fluid | 1 | 2008 | 24 | 0.310 |
Why?
|
| Dopaminergic Neurons | 2 | 2018 | 46 | 0.310 |
Why?
|
| Self Administration | 3 | 2019 | 419 | 0.290 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2018 | 87 | 0.280 |
Why?
|
| Inhalation Exposure | 1 | 2007 | 33 | 0.280 |
Why?
|
| Calcium | 2 | 2008 | 929 | 0.280 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 317 | 0.270 |
Why?
|
| Male | 15 | 2019 | 37321 | 0.270 |
Why?
|
| Limbic System | 2 | 2018 | 106 | 0.270 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2004 | 75 | 0.270 |
Why?
|
| Cannabinoid Receptor Antagonists | 1 | 2005 | 10 | 0.260 |
Why?
|
| Reward | 5 | 2018 | 201 | 0.250 |
Why?
|
| Biogenic Monoamines | 1 | 2004 | 18 | 0.240 |
Why?
|
| Substance-Related Disorders | 2 | 2005 | 1242 | 0.240 |
Why?
|
| Peroxynitrous Acid | 1 | 2004 | 55 | 0.240 |
Why?
|
| Substantia Nigra | 1 | 2004 | 102 | 0.230 |
Why?
|
| Corpus Striatum | 1 | 2004 | 279 | 0.210 |
Why?
|
| Hyperalgesia | 1 | 2022 | 18 | 0.210 |
Why?
|
| Serotonin | 1 | 2022 | 144 | 0.200 |
Why?
|
| Electric Stimulation | 3 | 2014 | 218 | 0.190 |
Why?
|
| Rats, Transgenic | 2 | 2018 | 24 | 0.180 |
Why?
|
| Neural Pathways | 2 | 2017 | 324 | 0.180 |
Why?
|
| Proteomics | 1 | 2022 | 246 | 0.180 |
Why?
|
| In Vitro Techniques | 3 | 2014 | 765 | 0.180 |
Why?
|
| Calcium Channels, N-Type | 1 | 2019 | 7 | 0.170 |
Why?
|
| Benzoxazines | 2 | 2018 | 20 | 0.170 |
Why?
|
| Naphthalenes | 2 | 2018 | 47 | 0.170 |
Why?
|
| Morpholines | 2 | 2018 | 79 | 0.170 |
Why?
|
| Remoxipride | 1 | 1999 | 1 | 0.170 |
Why?
|
| Dopamine Antagonists | 1 | 1999 | 65 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1745 | 0.160 |
Why?
|
| Receptors, Presynaptic | 1 | 2018 | 6 | 0.160 |
Why?
|
| Egtazic Acid | 1 | 2018 | 29 | 0.160 |
Why?
|
| Phenylenediamines | 1 | 2018 | 16 | 0.160 |
Why?
|
| Membrane Transport Modulators | 1 | 2018 | 23 | 0.160 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1664 | 0.160 |
Why?
|
| Carbamates | 1 | 2018 | 41 | 0.150 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 203 | 0.150 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 189 | 0.140 |
Why?
|
| Protein Binding | 1 | 2019 | 1027 | 0.140 |
Why?
|
| Phosphorylation | 1 | 2019 | 1200 | 0.140 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2018 | 435 | 0.120 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2014 | 25 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 76 | 0.120 |
Why?
|
| Neurotransmitter Agents | 1 | 2014 | 102 | 0.120 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 204 | 0.120 |
Why?
|
| Cannabinoids | 2 | 2004 | 90 | 0.110 |
Why?
|
| Mice | 2 | 2018 | 8474 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 2791 | 0.100 |
Why?
|
| Electrophysiology | 3 | 2003 | 160 | 0.100 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2010 | 7 | 0.090 |
Why?
|
| Alcoholism | 1 | 2018 | 1109 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2018 | 2689 | 0.090 |
Why?
|
| Morphine | 1 | 2010 | 76 | 0.090 |
Why?
|
| Receptors, AMPA | 1 | 2010 | 99 | 0.080 |
Why?
|
| Receptors, GABA-A | 1 | 2010 | 89 | 0.080 |
Why?
|
| Extracellular Fluid | 1 | 2007 | 29 | 0.070 |
Why?
|
| Presynaptic Terminals | 1 | 2007 | 34 | 0.070 |
Why?
|
| Microdialysis | 1 | 2007 | 147 | 0.070 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 122 | 0.070 |
Why?
|
| Solvents | 1 | 2007 | 109 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 981 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2007 | 236 | 0.060 |
Why?
|
| Apamin | 1 | 2004 | 13 | 0.060 |
Why?
|
| Receptors, GABA-B | 1 | 2004 | 10 | 0.060 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2004 | 8 | 0.060 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2004 | 27 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 61 | 0.060 |
Why?
|
| Caudate Nucleus | 1 | 2004 | 56 | 0.060 |
Why?
|
| Dronabinol | 1 | 2005 | 84 | 0.060 |
Why?
|
| Receptors, Drug | 1 | 2003 | 31 | 0.060 |
Why?
|
| Oxidopamine | 1 | 2003 | 42 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2003 | 64 | 0.050 |
Why?
|
| Amino Acids | 1 | 2003 | 131 | 0.050 |
Why?
|
| Time Factors | 2 | 2002 | 4655 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2002 | 187 | 0.050 |
Why?
|
| Kinetics | 1 | 2002 | 1047 | 0.050 |
Why?
|
| Hippocampus | 1 | 2003 | 471 | 0.040 |
Why?
|
| Chromatography, Gas | 1 | 1999 | 31 | 0.040 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 1999 | 13 | 0.040 |
Why?
|
| Prosencephalon | 1 | 2018 | 38 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2018 | 231 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 948 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2018 | 470 | 0.030 |
Why?
|
| Humans | 3 | 2015 | 68618 | 0.030 |
Why?
|
| Brain | 1 | 2004 | 2176 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2018 | 824 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 109 | 0.010 |
Why?
|
| Receptors, Cannabinoid | 1 | 2003 | 26 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 282 | 0.010 |
Why?
|
| United States | 1 | 2004 | 7367 | 0.010 |
Why?
|